1. Home
  2. KYMR vs NABL Comparison

KYMR vs NABL Comparison

Compare KYMR & NABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYMR
  • NABL
  • Stock Information
  • Founded
  • KYMR 2015
  • NABL 2000
  • Country
  • KYMR United States
  • NABL United States
  • Employees
  • KYMR N/A
  • NABL N/A
  • Industry
  • KYMR Medicinal Chemicals and Botanical Products
  • NABL Computer Software: Prepackaged Software
  • Sector
  • KYMR Health Care
  • NABL Technology
  • Exchange
  • KYMR Nasdaq
  • NABL Nasdaq
  • Market Cap
  • KYMR 2.2B
  • NABL 1.9B
  • IPO Year
  • KYMR 2020
  • NABL N/A
  • Fundamental
  • Price
  • KYMR $25.97
  • NABL $6.35
  • Analyst Decision
  • KYMR Buy
  • NABL Buy
  • Analyst Count
  • KYMR 13
  • NABL 4
  • Target Price
  • KYMR $56.69
  • NABL $9.38
  • AVG Volume (30 Days)
  • KYMR 847.3K
  • NABL 1.3M
  • Earning Date
  • KYMR 05-01-2025
  • NABL 05-08-2025
  • Dividend Yield
  • KYMR N/A
  • NABL N/A
  • EPS Growth
  • KYMR N/A
  • NABL 24.64
  • EPS
  • KYMR N/A
  • NABL 0.16
  • Revenue
  • KYMR $47,072,000.00
  • NABL $466,147,000.00
  • Revenue This Year
  • KYMR $16.24
  • NABL $7.38
  • Revenue Next Year
  • KYMR $22.41
  • NABL $9.67
  • P/E Ratio
  • KYMR N/A
  • NABL $39.69
  • Revenue Growth
  • KYMR N/A
  • NABL 10.49
  • 52 Week Low
  • KYMR $19.45
  • NABL $6.21
  • 52 Week High
  • KYMR $53.27
  • NABL $15.49
  • Technical
  • Relative Strength Index (RSI)
  • KYMR 44.70
  • NABL 34.64
  • Support Level
  • KYMR $24.43
  • NABL $6.48
  • Resistance Level
  • KYMR $26.06
  • NABL $6.81
  • Average True Range (ATR)
  • KYMR 2.36
  • NABL 0.35
  • MACD
  • KYMR 0.41
  • NABL 0.01
  • Stochastic Oscillator
  • KYMR 70.12
  • NABL 10.70

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. it also has a presence in the United Kingdom and all other International regions.

Share on Social Networks: